Tag: Substance abuse

Posted on

Millions of People in Canada Are Finding AI-Enabled Support for Mental Health Effective Amid Ongoing Questions Around Trust.

(OTTAWA) July 8, 2026 — New polling shows approximately six million people in Canada used AI-enabled tools for mental health support in the past year and most find them effective. Today, the Mental Health Commission of Canada (the Commission), in partnership with Mental Health Research Canada (MHRC) and Pollara Strategic Insights, releases the first nationally representative data on how people in Canada engage with digitally supported mental health tools, including AI and virtual care, across every province and demographic.

Quick Facts:

  • 1 in 7 people in Canada used AI mental health tools in the past year
  • Three out of four who used AI and virtual mental health services found them effective for their well-being
  • Only 14 % trust AI tools, just 2% trust them completely
  • 40 % of AI users said they were more likely to seek professional care
  • Nearly half (45%) who accessed mental health care did so virtually, in whole or in part

WHY IT MATTERS

People in Canada are turning to AI as a convenient way to access mental health support.  AI-enabled tools may offer greater convenience and accessibility. Among those surveyed, AI is being used because it is:

  • Free or low-cost; 46% of AI users cite this as the reason they use it during a time when financial stress is itself a cause for anxiety.
  • Always available; 44% of AI users cite 24/7 access.
  • Immediate and convenient; it can be used from anywhere without travelling or waiting for an appointment. For someone in rural Canada, it saves time and travel costs.
  • Seemingly private; 39 % of AI service users cite private, anonymous support as a reason for use, while privacy and data protection remain key public concerns.

AI is most used for general well-being (42%), companionship (36%), and mild-to-moderate stress (36%), and 40% of AI users said they were more likely to seek professional care.

WHO IS USING IT AND HOW MUCH DO THEY TRUST IT?

Use is higher among people in Canada under 35 (27%; 29% among men aged 25–34), newcomers to Canada (28%), racialized people in Canada (23%), and 2SLGBTQI+ communities (20%), populations that may experience greater barriers to traditional care.

Overall, trust remains low, particularly for AI-enabled tools, where only 2% of people in Canada trust them completely. People in Canada over 55 show the lowest adoption and trust.

VIRTUAL CARE: EFFECTIVE AND MORE TRUSTED BUT FALLS SHORT OF IN-PERSON SERVICES

45% of people in Canada who used mental health services in the past year did so virtually, with 75% reporting positive outcomes. However, nearly 1 in 3 prefer a hybrid model that combines virtual and in-person services. The data signals what people in Canada need: well-designed tools for safer digital mental health care that they can trust.

THE COMMISSION OFFERS GUIDANCE FOR THE DIGITAL MENTAL HEALTH ERA

The Commission is Canada’s trusted resource for safe digital mental health — assessing apps and tools, setting evidence-based standards, and leading the national conversation on guidance for AI in mental health and substance use health care.

As virtual services and AI-enabled tools continue to expand rapidly across the mental health landscape, there is a growing need for evidence-based insight into how people in Canada engage with, understand, and perceive them. The Commission partnered with MHRC to leverage their ongoing national polling initiative and provide timely insights into usage, attitudes, and concerns related to e-mental health and AI.

The polling is clear: people in Canada want to close the gap between availability and trust. The Commission is working with the Canadian Centre on Substance Use and Addiction and collaborators, provincial governments, technology developers, and health system partners to establish guidance for AI.

“Six million people in Canada have already used AI for mental health support and most found it convenient and effective for their well-being. It is critical that AI is safe and equitable to increase public trust and reduce harms.” – Lili-Anna Pereša, President and Chief Executive Officer, Mental Health Commission of Canada

“The people turning to digitally-supported mental health tools are often those facing some of the greatest barriers to care. Making sure these tools are safe, effective, evidence-based and human-centred is a matter of equity. Ongoing research is essential to understanding where they help and where safeguards are needed.”– Akela Peoples, Chief Executive Officer, Mental Health Research Canada

About Mental Health Commission of Canada
As an independent, not-for-profit with charitable status, the Commission collaborates with leading experts and organizations nationally and internationally, including with people with lived and living experience, to develop national guidelines, standards and strategies, promote innovation and best practices, reduce stigma, increase mental health literacy, and support all levels of government to improve mental health outcomes for everyone living in Canada.  The Commission is Canada’s trusted resource for digital mental health best practices with the e-Mental Health Strategy for Canada, app assessment, e-modules for e-mental health implementation, and AI guidance for mental health and substance use health.

About Mental Health Research Canada
As an independent national charity, MHRC works hard to enable a future where mental health in Canada is transformed using evidence, data and stakeholder engagement. We unite researchers, communities, and people with lived experience to bridge gaps in care through national population polling, rapid data reporting, and partnerships that inform policy to improve outcomes. Learn more at www.mhrc.ca

About the Polling
Conducted by Pollara Strategic Insights in partnership with Mental Health Research Canada and the Mental Health Commission of Canada, this national poll (n=3,519) is the first representative data on AI use for mental health in Canada. Full findings: https://mentalhealthcommission.ca/AI-polling-report

About the Funding
The views in this report solely represent the views of the Mental Health Commission of Canada. Production of this report is made possible through financial contribution from Health Canada.

Media Contact
Heather Bakken, Pendulum Group
email: heather@pendulumgroup.ca 
cell: 613-406-5432

The post Millions of People in Canada Are Finding AI-Enabled Support for Mental Health Effective Amid Ongoing Questions Around Trust. appeared first on Mental Health Commission of Canada.

Posted on

Research progress on addictive features and reward circuit mechanisms in non-suicidal self-injury and the feasibility of precision neuromodulation

Non-Suicidal Self-Injury (NSSI) presents a significant public health challenge; however, its underlying neurobiological mechanisms remain insufficiently understood, limiting the development of targeted interventions. Emerging evidence suggests that NSSI exhibits core addictive features, such as compulsive urges and tolerance, which may be driven by dysfunctions in the brain’s reward circuitry. This review synthesizes current research on the neural overlaps between NSSI and addiction, specifically focusing on the dysregulation of the ventral striatum and prefrontal cortex. Based on this mechanistic framework, we propose the potential of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)—a high-dose, functional connectivity-guided transcranial magnetic stimulation protocol—as a precision treatment for NSSI. By targeting specific reward network deficits, SAINT may offer a novel, rapid-acting therapeutic strategy for patients who do not respond to conventional pharmacological or psychological interventions.
Posted on

New sa‑mRNA and LNP Platform to Support Korea’s Hantavirus Vaccine Initiative

With hantavirus thrust into the public spotlight in recent months, a new effort in South Korea aims to advance vaccine development against the rodent-borne pathogen using mRNA technologies.

Korea University College of Medicine has been selected to lead a government-supported initiative focused on developing next-generation hantavirus vaccines. The program will be conducted through the institution’s Vaccine Innovation Center.

Hantaviruses are carried primarily by rodents and can infect humans through exposure to contaminated urine, droppings, or saliva. Depending on the viral strain, infection can cause hantavirus pulmonary syndrome (HPS), a severe respiratory illness, or hemorrhagic fever with renal syndrome (HFRS), a disease characterized by kidney dysfunction and bleeding complications. Although relatively rare, hantavirus infections can carry high mortality rates and remain a public health concern in parts of Asia, Europe, and the Americas.

The renewed focus on vaccine development comes amid growing interest in preparedness for emerging and re-emerging infectious diseases. While mRNA technology gained worldwide recognition during the COVID-19 pandemic, researchers have increasingly explored its application against a broader range of viral threats.

According to Korea University, the newly funded program will leverage the rapid development potential of mRNA platforms to generate vaccine candidates targeting hantavirus infection.

“The Vaccine Innovation Center is the only private-sector vaccine research and development institute in Korea established to carry forward the scientific legacy of Dr. Ho-Wang Lee, who first discovered the hantavirus,” said Hee-Jin Cheong, MD, PhD, director of the Vaccine Innovation Center. “Beginning with hantavirus vaccine development, we aim to lead infectious disease research in Korea and contribute to improving public health.”

The initiative will draw on two domestically developed technologies: self-amplifying mRNA (sa-mRNA) and a next-generation lipid nanoparticle (LNP) delivery platform. Unlike conventional mRNA vaccines, sa-mRNA contains genetic instructions that enable replication of the RNA within cells, potentially generating stronger immune responses while requiring lower doses. The platform is intended to support rapid vaccine development and manufacturing while reducing dependence on overseas intellectual property.

The project builds on research conducted over the past two years at the Vaccine Innovation Center in collaboration with Moderna. The new program will seek to translate preclinical study findings into a next-generation vaccine candidate developed in partnership with biotechnology companies.

Under the two-year project timeline, researchers will spend the first year optimizing vaccine candidates and evaluating their efficacy. The second year will focus on Good Manufacturing Practice (GMP)-compliant production and safety testing.

Researchers have increasingly viewed mRNA platforms as particularly attractive because they can be rapidly redesigned when emerging threats arise. Lessons learned from COVID-19 vaccine development have helped establish manufacturing, regulatory, and clinical frameworks that may accelerate future vaccine programs.

As concern over emerging infectious diseases continues to shape global health priorities, programs such as this one may help expand the range of vaccine technologies available to combat pathogens that have historically received limited research attention.

The post New sa‑mRNA and LNP Platform to Support Korea’s Hantavirus Vaccine Initiative appeared first on GEN – Genetic Engineering and Biotechnology News.

Posted on

Case Report: Delirium and complications resulting from the abuse of compound liquorice tablets

BackgroundCompound liquorice tablets is a cough-suppressing compound formulation containing opium powder and liquorice. With the strict regulation of traditional opioids, this medication has emerged as a novel alternative for substance abuse due to its easy accessibility and low cost; however, its addiction potential and severe adverse complications remain underrecognized and insufficiently addressed in clinical practice.Case summaryThe patient is a 29-year-old male who began self-medicating with compound liquorice tablets for a dry cough after COVID-19 infection. His daily dosage gradually escalated to 200–600 tablets within two years, resulting in established drug dependence. Two days after discontinuing the medication, he developed delirium manifested as confusion, disorientation, visual hallucinations and psychomotor agitation, accompanied by palpitations, hypertension, tremors, rhinorrhea, vomiting, severe hypokalemia, and bilateral lower limb edema. Organic brain diseases were excluded by systematic examinations. According to the ICD-10 diagnostic criteria, he was diagnosed with opioid-induced mental and behavioral disorders, hypokalemia and hypertension. We implemented a benzodiazepine tapering regimen to control delirium and sympathetic excitation associated with withdrawal symptoms, combined with antidepressants and antipsychotics to improve mood, anxiety, and psychotic symptoms, Under the guidance of a cardiologist, we actively managing hypertension and correcting internal environmental disturbances. Following comprehensive management, the patient’s withdrawal symptoms and delirium resolved, with stable emotional state and blood pressure, resulting in successful withdrawal.ConclusionThis is the first reported case of delirium caused by withdrawal from compound liquorice tablets. It provides preliminary insights for clinical identification, diagnosis, and multidisciplinary management of dependence on compound liquorice tablets, as well as related withdrawal symptoms and complications. This case also alerts to the emerging risk of abuse associated with new substances such as compound liquorice tablets and underscores the need for stricter prescription controls and patient education regarding the risks of abuse.
Posted on

Fatherhood and addictive disorders: experiences and support needs – results of a qualitative interview study

ObjectivesParental addictive disorders are a major public health problem. Despite already known negative effects, the parental role of men seeking help is rarely acknowledged within addiction support services. This study aims to identify existing relations between fatherhood and addiction, and the resulting support needs of affected fathers.MethodsFor data collection 15 fathers with addictive disorders were interviewed by using qualitative, guided interviews. The data material was analyzed using qualitative content analysis.ResultsThe effects of addictive disorders on fatherhood are predominantly unfavorable. Conversely, fatherhood can have consumption-reducing as well as consumption-increasing effects. In this context, five topics were identified in which fathers expressed specific support needs. Particularly fathers with substance use disorders expressed their need for further support, while fathers with behavioral addictions expressed a lesser need.ConclusionsPaying attention to fatherhood in the context of addiction services provides a starting point for increasing the motivation to change. Individual support needs should be considered when implementing father-specific programs. Not only the fathers themselves, but also their children can benefit from successful treatment and expected changes in fatherhood.
Posted on

Mechanisms and durability of residential treatment for co-occurring gambling and substance use disorders: a mixed-methods eight-year follow-up study

IntroductionGambling disorder is associated with substantial psychosocial harm, yet long-term outcome data for residential treatment programs remain limited.MethodsThis mixed-methods study examined outcomes among 36 former residential treatment clients assessed between six months and eight years following discharge from a program treating co-occurring gambling and substance use disorders. Structured interviews evaluated gambling behavior, psychiatric symptoms, substance use, and functional outcomes, supplemented by qualitative thematic analysis.ResultsSixty-one percent reported gambling following discharge; however, participants demonstrated significant improvements in gambling craving strength, life satisfaction, gambling-related interference, and alcohol use. Employment increased from 25.0% to 66.7%. Treatment non-completion was associated with earlier return to gambling and higher odds of post-discharge gambling. Qualitative analysis identified environmental restructuring, urge-management skill development, structured routines, and post-discharge support as key recovery mechanisms.DiscussionResidential treatment may support durable improvements in functioning and gambling-related distress among individuals with severe gambling disorder, although causal conclusions are limited by the observational design.
Posted on

The UK’s generational tobacco ban might not work. I’m supporting it anyway.

As the parent of two little girls, I often think about how their childhood is different from mine. The seven-year-old is learning about AI at school. The five-year-old is given internet-based homework every week. And they are both absolutely repulsed by the idea of smoking.

That was not the prevailing sentiment when I was young. My parents smoked. The customers at our family’s restaurant smoked. Cartoon characters smoked. My friends and I would buy little cigarette-box-shaped packets of sugary white sticks and pretend to smoke in the playground. Smoking was a central part of our culture.

Which is why the UK’s recent passing of a generational sales ban on tobacco products feels like such a big deal. As part of the Tobacco and Vapes Act 2026, retailers are prohibited from selling tobacco products to anyone born after January 1, 2009, in perpetuity. It doesn’t matter when those people turn 18—or 38 or 68, for that matter. It will always be illegal to sell to anyone born after that date.

This is what’s described as an “endgame” approach. While many tobacco control strategies—such as taxation or gory imagery—aim to reduce consumption, policies like the UK’s are designed to eliminate it entirely. It’s a new approach, and no one knows whether it will work.

The Maldives was the first country to implement a generational smoking ban, in November last year. It’s too soon to say how that has panned out.

Nor do we know if these laws will even last. In 2022, New Zealand passed a similar generational sales ban as part of a broader anti-smoking law. But it was never enacted—the law was repealed by a new government in February 2024.

In the UK, both major parties support the ban. But Nigel Farage, whose right-wing party has seen a recent surge in support, has promised that “the generational smoking ban will not last long if Reform gets the chance to start rebuilding our mismanaged country.”

Chris Bostic, an attorney and former policy director for the advocacy group Action on Smoking and Health, says he and his colleagues began promoting the idea of a generational ban in the United States 11 years ago. Back then, they struggled to win support, even from major health charities. “People said we were crazy … [and] that this was impossible,” he says. Opponents argued that bans would infringe on personal freedoms.

“The public health argument is: Well, what about freedom from addiction?” says Britta Matthes, a tobacco control researcher at the University of Bath in the UK. Most people who smoke began when they were teenagers, want to quit, and wish they’d never started. Tobacco is arguably the most harmful consumer product of all time. It will kill half its users who don’t quit, according to the World Health Organization.

It also kills people who don’t smoke. Of the 7 million who die from tobacco every year, 1.6 million are nonsmokers who were exposed to secondhand smoke, according to the WHO.

Generational sales bans are a long-term strategy that will only protect future smokers. Most experts agree that people who already smoke should be a main consideration for any policy, and that a multipronged approach is probably the best way to go. Janet Hoek at the University of Otago, who has explored tobacco control policies in New Zealand, believes that enforcing very low limits on nicotine levels and banning filters—an environmental scourge that does not make smoking safer, as many people believe—might be a “powerful combination,” for example.

But preventing teenagers from starting to smoke in the first place is an enticing prospect, even among the majority of people who smoke. And it’s starting to look a lot less radical.

The US has quietly been making progress on a smaller scale. Since 2021, Brookline, a town in the Boston area, has banned the sale of tobacco products to anyone born after January 1, 2000. The idea has spread. Today there are 23 towns in Massachusetts with similar bans, says Bostic. Nine towns across Minnesota, New York, and California have implemented other endgame policies.

The UK law has normalized the idea more than ever, he adds. His colleagues are already fielding calls from health agencies around the world. “People [are] saying, Wow I can’t believe the UK just did this—can we do this here?” he says.

Norms change. Like many other millennials, I vividly remember my first night out after a ban on indoor smoking took effect. My clothes didn’t stink! My hair still felt clean! And my throat wasn’t scratchy the next morning! Now that’s just normal. I hope a tobacco-free world can be the new normal for my kids.

Posted on
<![CDATA[Expert explores fast-acting depression treatments, psilocybin trial pitfalls, and why stigma still limits buprenorphine access for opioid use disorder.]]>
Posted on
<![CDATA[Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.]]>